Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer.
Journal: Research square
Published: July 10, 2026
Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer.
Journal: Prostate cancer and prostatic diseases
Published: March 09, 2026
Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer.
Journal: JCO precision oncology
Published: December 05, 2025
Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).
Journal: Clinical genitourinary cancer
Published: November 09, 2025
SPOP Mutations in Veterans With Prostate Cancer and Outcomes With Doublet and Triplet Therapy in De Novo Metastatic Hormone Sensitive Prostate Cancer.
Journal: The Prostate
Published: September 15, 2025
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.
Journal: JCO precision oncology
Published: August 23, 2024
Intensification of androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: patient selection and overview of doublet and triplet therapy data.
Journal: Advances in oncology
Published: July 29, 2024
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.
Journal: Clinical genitourinary cancer
Published: April 08, 2024
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
Journal: JCO precision oncology
Published: April 05, 2024
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 11, 2023
Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
Journal: JAMA network open
Published: September 18, 2023
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
Journal: Prostate cancer and prostatic diseases
Published: July 24, 2023
Last Updated: 09/26/2026